GALAPAGOS NV-SPON ADR (GLPG)

US36315X1019 - ADR

23.84  -0.14 (-0.58%)

Fundamental Rating

3

Overall GLPG gets a fundamental rating of 3 out of 10. We evaluated GLPG against 572 industry peers in the Biotechnology industry. GLPG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GLPG is valued expensive and it does not seem to be growing.



Quickly go to:

3

1. Profitability

1.1 Basic Checks

GLPG had positive earnings in the past year.
GLPG had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: GLPG reported negative net income in multiple years.
In the past 5 years GLPG reported 4 times negative operating cash flow.

1.2 Ratios

With an excellent Return On Assets value of 7.85%, GLPG belongs to the best of the industry, outperforming 95.75% of the companies in the same industry.
GLPG's Return On Equity of 11.57% is amongst the best of the industry. GLPG outperforms 95.58% of its industry peers.
Industry RankSector Rank
ROA 7.85%
ROE 11.57%
ROIC N/A
ROA(3y)-0.58%
ROA(5y)-0.92%
ROE(3y)-1.65%
ROE(5y)-2.24%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Profit Margin, with a value of 58.03%, GLPG belongs to the top of the industry, outperforming 99.11% of the companies in the same industry.
GLPG does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 58.03%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

GLPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GLPG has about the same amount of shares outstanding.
The number of shares outstanding for GLPG has been increased compared to 5 years ago.
Compared to 1 year ago, GLPG has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of 1.56, we must say that GLPG is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.56, GLPG is in the better half of the industry, outperforming 69.73% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that GLPG is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.00, GLPG perfoms like the industry average, outperforming 47.08% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.56
ROIC/WACCN/A
WACC7.68%

2.3 Liquidity

A Current Ratio of 10.05 indicates that GLPG has no problem at all paying its short term obligations.
With an excellent Current ratio value of 10.05, GLPG belongs to the best of the industry, outperforming 80.71% of the companies in the same industry.
GLPG has a Quick Ratio of 9.87. This indicates that GLPG is financially healthy and has no problem in meeting its short term obligations.
GLPG's Quick ratio of 9.87 is amongst the best of the industry. GLPG outperforms 80.53% of its industry peers.
Industry RankSector Rank
Current Ratio 10.05
Quick Ratio 9.87

More info and screens

1

3. Growth

3.1 Past

GLPG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 236.12%, which is quite impressive.
GLPG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.23%.
Measured over the past years, GLPG shows a decrease in Revenue. The Revenue has been decreasing by -2.02% on average per year.
EPS 1Y (TTM)236.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-297.44%
Revenue 1Y (TTM)-16.23%
Revenue growth 3Y-18.51%
Revenue growth 5Y-2.02%
Sales Q2Q%-50.14%

3.2 Future

The Earnings Per Share is expected to decrease by -28.71% on average over the next years. This is quite bad
GLPG is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -8.76% yearly.
EPS Next Y-131.32%
EPS Next 2Y-47.15%
EPS Next 3Y-36.26%
EPS Next 5Y-28.71%
Revenue Next Year-41.85%
Revenue Next 2Y-29.03%
Revenue Next 3Y-20.35%
Revenue Next 5Y-8.76%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 7.38, the valuation of GLPG can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of GLPG indicates a rather cheap valuation: GLPG is cheaper than 98.41% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.28, GLPG is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for GLPG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 7.38
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as GLPG's earnings are expected to decrease with -36.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-47.15%
EPS Next 3Y-36.26%

More info and screens

0

5. Dividend

5.1 Amount

GLPG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALAPAGOS NV-SPON ADR

NASDAQ:GLPG (1/15/2025, 9:53:02 AM)

23.84

-0.14 (-0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2024-10-30/amc
Earnings (Next)N/A N/A
Inst Owners32.48%
Inst Owner Change0.01%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap1.57B
Analysts53
Price Target35.64 (49.5%)
Short Float %3.3%
Short Ratio6.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)608.66%
Min EPS beat(2)164.74%
Max EPS beat(2)1052.58%
EPS beat(4)4
Avg EPS beat(4)379.2%
Min EPS beat(4)139.83%
Max EPS beat(4)1052.58%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.33%
PT rev (3m)-17.41%
EPS NQ rev (1m)-1.28%
EPS NQ rev (3m)-153.72%
EPS NY rev (1m)0%
EPS NY rev (3m)-323.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.39%
Revenue NY rev (1m)3.85%
Revenue NY rev (3m)8.47%
Valuation
Industry RankSector Rank
PE 7.38
Fwd PE N/A
P/S 2.64
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 0.58
EV/EBITDA N/A
EPS(TTM)3.23
EY13.55%
EPS(NY)-0.55
Fwd EYN/A
FCF(TTM)-7.12
FCFYN/A
OCF(TTM)-5.82
OCFYN/A
SpS9.02
BVpS45.25
TBVpS41.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.85%
ROE 11.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 58.03%
GM N/A
FCFM N/A
ROA(3y)-0.58%
ROA(5y)-0.92%
ROE(3y)-1.65%
ROE(5y)-2.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 192.65%
Cap/Sales 14.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.05
Quick Ratio 9.87
Altman-Z 1.56
F-Score5
WACC7.68%
ROIC/WACCN/A
Cap/Depr(3y)89.21%
Cap/Depr(5y)224.68%
Cap/Sales(3y)10.26%
Cap/Sales(5y)10.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)236.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-297.44%
EPS Next Y-131.32%
EPS Next 2Y-47.15%
EPS Next 3Y-36.26%
EPS Next 5Y-28.71%
Revenue 1Y (TTM)-16.23%
Revenue growth 3Y-18.51%
Revenue growth 5Y-2.02%
Sales Q2Q%-50.14%
Revenue Next Year-41.85%
Revenue Next 2Y-29.03%
Revenue Next 3Y-20.35%
Revenue Next 5Y-8.76%
EBIT growth 1Y-5.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.19%
EBIT Next 3Y4.12%
EBIT Next 5Y-2.6%
FCF growth 1Y18.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.75%
OCF growth 3YN/A
OCF growth 5YN/A